CD8A and cancer: These prodrug nanocarriers induce immunogenic cell death, enhance the infiltration of cytotoxic T cells (CD8+ T cells), and suppress Treg cells, MDSCs, and TAMs in the TME, thereby effectively promoting T cell/Treg cell ratio for cancer immunotherapy [301].